Literature DB >> 9073315

Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin.

U Masanek1, G Stammler, M Volm.   

Abstract

Doxorubicin- (OAW-dox, SK-OV-dox), taxol- (OAW-tax, SK-OV-tax) and cisplatin- (SK-OV-cis) resistant cells derived from the parental OAW-42 and SK-OV-3 cell lines were established. OAW-42 sublines showed high resistance, the SK-OV-3 sublines only low resistance. OAW-42 sublines showed a cross-resistance profile typical of multidrug resistance (MDR). The sublines of SK-OV-3 showed a cross-resistance profile different from the OAW-42 sublines. The mRNA expression of several resistance proteins and related factors was analyzed. An overexpression of P-glycoprotein 170 (P-170), glutathione-S-transferase-pi (GST-pi), thymidylate synthase (TS), glutathione peroxidase (GP) and c-jun was found in OAW-dox and OAW-tax cells. Additionally, OAW-tax cells expressed a higher mRNA level of protein kinase Cbeta2. DNA analysis revealed a 2-fold gene amplification of P-170, whereas the genes for GST-pi, TS and GP were not amplified. SK-OV-dox and SK-OV-tax cells showed a decreased level of histone 3 (H3) and TS mRNA. This shows that the sublines of OAW-42 developed resistance by co-expression of several resistance-related proteins and proto-oncogenes whereas the sublines of SK-OV-3 expressed resistance by decreased expression of the proliferation-dependent proteins H3 and TS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9073315     DOI: 10.1097/00001813-199702000-00010

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

1.  The extended-MDR phenotype.

Authors:  R Davey; M Davey
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

2.  KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.

Authors:  T Jiffar; T Yilmaz; J Lee; E Hanna; A El-Naggar; D Yu; J N Myers; M E Kupferman
Journal:  Oncogene       Date:  2011-03-07       Impact factor: 9.867

3.  p53 expression and resistance against paclitaxel in patients with metastatic breast cancer.

Authors:  M Schmidt; A Bachhuber; A Victor; E Steiner; M Mahlke; H A Lehr; H Pilch; W Weikel; P G Knapstein
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-25       Impact factor: 4.553

4.  High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance.

Authors:  Michael Boettcher; Frank Kischkel; Jörg D Hoheisel
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

5.  Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells.

Authors:  K E Odening; W Li; R Rutz; S Laufs; S Fruehauf; Z Fishelson; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

Review 6.  Mechanisms of Resistance to Conventional Therapies for Osteosarcoma.

Authors:  Louise Marchandet; Morgane Lallier; Céline Charrier; Marc Baud'huin; Benjamin Ory; François Lamoureux
Journal:  Cancers (Basel)       Date:  2021-02-08       Impact factor: 6.639

7.  The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers.

Authors:  T Goto; M Takano; J Hirata; H Tsuda
Journal:  Br J Cancer       Date:  2008-03-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.